Wire · operational-macro
AbbVie lands FDA approval for Cerevel-origin Parkinson's drug Juvmo
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
AbbVie received FDA approval for Juvmo (tavapadon), the first selective D1/D5 receptor agonist for Parkinson's disease, following its acquisition of Cerevel Therapeutics. This drug offers a new mechanism of action distinct from existing dopamine agonists and showed significant clinical benefits in the Phase III TEMPO trials.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it.
◆ ◆ The Wire takeaway
AbbVie's drug approval reshapes Parkinson's treatment options and raises the bar for new therapies targeting dopamine receptors. You must now consider the competitive edge of selective D1/D5 agonists in the CNS treatment space for differentiation.
◆ Coverage
5 sources · 28 Sep 2026
◆ Related on Wire
◆ Topics